• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PDE3A Gene Record

  • Summary
  • Interactions
  • Claims
  • PDE3A 5139 Druggable Genome

    Alternate Names:

    5139
    PHOSPHODIESTERASE 3A
    PDE3A
    CGI-PDE
    CGI-PDE A
    CGI-PDE-A
    HTNB
    123805
    8778
    ENSG00000172572
    OTTHUMG00000168962
    Q14432
    PDE3A_HUMAN
    PDE3
    PHOSPHODIESTERASE 3
    CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE A
    Cyclic GMP-inhibited phosphodiesterase A
    CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE A (EC 3.1.4.17) (CYCLIC GMP INHIBITED PHOSPHODIESTERASE A) (CGI-PDE A). [SOURCE:UNIPROT/SWISSPROT;ACC:Q14432]
    PA33126
    T33754
    T88975

    Gene Info:

    Target Subclass 3.1.4
    Transmembrane Helix Count 6
    Target Main Class Enzymes
    Target Class Enzymes
    Target Subclass EC:3.1.4
    Target Subclass EC:3.1.4.17
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME
    Interpro Type Domain
    Interpro Short Name PDEase_catalytic_dom
    Interpro Acc IPR002073
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name 3'5'-cyclic nucleotide phosphodiesterase, catalytic domain
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Schrör, 2002, The pharmacology of cilostazol., Diabetes Obes Metab
    Mokry et al., 2008, Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity., J. Physiol. Pharmacol.
    Hong et al., 2006, Cilostazol: therapeutic potential against focal cerebral ischemic damage., Curr. Pharm. Des.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Parkkonen et al., 2008, Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol., Pulm Pharmacol Ther
    Yoshida H et al., 2012, K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model., PLoS One
    Kajikawa et al., 2006, Changes in submaxillary gland gene expression in F344 rats by multiple dosing of theophylline., Exp. Anim.
    Wu et al., 2004, KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels., Br. J. Pharmacol.
    Rickards et al., 2003, Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation., J. Vet. Pharmacol. Ther.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Venuti et al., 1988, Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline., J. Med. Chem.
    An R et al., 2019, PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth., Am J Cancer Res
    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension
    Hirota et al., 2002, Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs., Acta Anaesthesiol Scand
    Lefièvre et al., 2002, Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa., Biol. Reprod.
    Küthe et al., 2000, Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis., Eur. Urol.
    Zhang et al., 2002, Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis., Mol. Pharmacol.
    Shakur et al., 2002, Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart., Cardiovasc Drugs Ther
    Cone et al., 1999, Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells., J. Cardiovasc. Pharmacol.
    Sandroni et al., 2006, Enoximone in cardiac arrest caused by propranolol: two case reports., Acta Anaesthesiol Scand
    Boldt et al., 2007, Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone., Expert Opin Pharmacother
    Kucuk et al., 2009, Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury., J. Surg. Res.
    Kobayashi et al., 2002, Effects of amrinone on hepatic ischemia-reperfusion injury in rats., J. Hepatol.
    Ko et al., 2009, Myocardial cyclic AMP augmentation with high-dose PDEIII inhibitor in terminal warm blood cardioplegia., Ann Thorac Cardiovasc Surg
  • ANAGRELIDE   PDE3A

    Interaction Score: 17.67

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17016423 17139284 11752352 2846839 31598394


    Sources:
    TTD

  • MILRINONE   PDE3A

    Interaction Score: 13.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    12135876 10859452 12181427 12652111 11752352 10511123


    Sources:
    TdgClinicalTrial TEND TTD

  • K-134   PDE3A

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23110051


    Sources:
    TTD

  • ENOXIMONE   PDE3A

    Interaction Score: 3.68

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16987374 17714066


    Sources:
    TdgClinicalTrial TEND TTD

  • INAMRINONE LACTATE   PDE3A

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Phosphodiesterase 3A inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MILRINONE LACTATE   PDE3A

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Phosphodiesterase 3A inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BEMORADAN   PDE3A

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CILOSTAZOL   PDE3A

    Interaction Score: 2.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Phosphodiesterase 3A inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    12180353 19218671 16472148 11752352 18282775


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • ANAGRELIDE HYDROCHLORIDE   PDE3A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Phosphodiesterase 3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OXTRIPHYLLINE   PDE3A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Phosphodiesterase 3 inhibitor

    PMIDs:
    16651698 15237094 12887610


    Sources:
    ChemblInteractions TTD

  • TIPELUKAST   PDE3A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • OLPRINONE   PDE3A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • AMINOPHYLLINE   PDE3A

    Interaction Score: 1.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Phosphodiesterase 3 inhibitor

    PMIDs:
    11939921 11752352


    Sources:
    ChemblInteractions TTD

  • INAMRINONE   PDE3A

    Interaction Score: 1.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    18468627 12076859 19901885 11752352


    Sources:
    TdgClinicalTrial TEND

  • THEOPHYLLINE   PDE3A

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Phosphodiesterase 3 inhibitor
    Trial Name ADC4022, low-dose inhaled theophylline

    PMIDs:
    16651698 15237094 12887610


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • VESNARINONE   PDE3A

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DYPHYLLINE   PDE3A

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Phosphodiesterase 3A inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THEOPHYLLINE SODIUM GLYCINATE   PDE3A

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Phosphodiesterase 3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROCHLOROTHIAZIDE   PDE3A

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • PENTOXIFYLLINE   PDE3A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 3',5'-cyclic phosphodiesterase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIPYRIDAMOLE   PDE3A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 3',5'-cyclic phosphodiesterase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • Ensembl: ENSG00000172572

    • Version: 101_38

    Alternate Names:
    PDE3A Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000172572

    • Version: 26-July-2011

    Alternate Names:
    PDE3A Display Id
    CGMP-INHIBITED 3',5'-CYCLIC PHOSPHODIESTERASE A (EC 3.1.4.17) (CYCLIC GMP INHIBITED PHOSPHODIESTERASE A) (CGI-PDE A). [SOURCE:UNIPROT/SWISSPROT;ACC:Q14432] Description
    ENSG00000172572 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: Q14432

    • Version: 01-August-2011

    Alternate Names:
    PDE3A_HUMAN Uniprot Id
    PDE3A Gene Symbol
    ENSG00000172572 Ensembl Gene Id

    Gene Info:
    Target Subclass 3.1.4
    Transmembrane Helix Count 6
    Target Main Class Enzymes

    Publications:

  • TdgClinicalTrial: Q14432

    • Version: January-2014

    Alternate Names:
    PDE3A Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.1.4
    Target Subclass EC:3.1.4.17

    Publications:

  • HopkinsGroom: Q14432

    • Version: 11-September-2012

    Alternate Names:
    PDE3A_HUMAN Uniprot Id
    5139 Entrez Gene Id
    PDE3A Uniprot Gene Name

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Interpro Type Domain
    Interpro Short Name PDEase_catalytic_dom

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: PDE3A

    • Version: 18-August-2020

    Alternate Names:
    PA33126 PharmGKB ID

    Gene Info:

    Publications:
    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension

  • TTD: Phosphodiesterase 3

    • Version: 2020.06.01

    Alternate Names:
    PDE3 TTD Gene Abbreviation
    T33754 TTD Target ID

    Gene Info:

    Publications:
    Yoshida H et al., 2012, K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model., PLoS One

  • HingoraniCasas: ENSG00000172572

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000172572 Gene Symbol
    PDE3A Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: PDE3A

    • Version: chembl_23

    Alternate Names:
    PDE3A GENE_SYMBOL
    cGMP-inhibited 3',5'-cyclic phosphodiesterase A UNIPROT
    Cyclic GMP-inhibited phosphodiesterase A UNIPROT

    Gene Info:

    Publications:

  • TTD: Phosphodiesterase 3A

    • Version: 2020.06.01

    Alternate Names:
    PDE3A TTD Gene Abbreviation
    T88975 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: PDE3A

    • Version: 01-February-2022

    Alternate Names:
    cGMP-inhibited 3',5'-cyclic phosphodiesterase A Gene Name
    Q14432 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21